Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

CONCLUSION: FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
PMID: 31655812 [PubMed - as supplied by publisher]

Source: American Journal of Nephrology - October 24, 2019 Category: Urology & Nephrology Authors: Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G, on behalf of the FIDELIO-DKD study investigators Tags: Am J Nephrol Source Type: research